Amvuttra (vutrisiran) is a medication used to treat hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adults [1]. This condition is characterized by the buildup of abnormal amyloid protein in organs and tissues [1]. Amvuttra works by targeting and reducing the production of transthyretin (TTR) protein [1].
How does Amvuttra work for hATTR amyloidosis?
Amvuttra is an RNA interference (RNAi) therapeutic that is administered via subcutaneous injection [1]. It is designed to target messenger RNA (mRNA) produced by the liver that codes for the TTR protein [2]. By reducing TTR mRNA levels, Amvuttra decreases the production of both normal and mutated TTR protein, thereby lowering the amount of amyloid that can form in the body [1][2].
What is the difference between Amvuttra and other TTR amyloidosis treatments?
Amvuttra is a small interfering RNA (siRNA) therapeutic. Other treatments for hATTR amyloidosis include TTR stabilizers like tafamidis, which prevent TTR from misfolding and forming amyloid deposits [3]. Another RNAi therapeutic, patisiran (Onpattro), is also available and works similarly to Amvuttra by reducing TTR protein production [4]. The choice of treatment may depend on the stage of the disease and individual patient factors.
When is Amvuttra expected to have patent expiry?
Information on the specific patent expiry dates for Amvuttra is available through specialized drug patent databases. Resources like DrugPatentWatch.com track these timelines, which are crucial for understanding when generic or biosimilar competition might emerge [5].
What clinical trial data supports Amvuttra's effectiveness?
The efficacy and safety of Amvuttra were demonstrated in the APOLLO Phase 3 study [1]. This study showed statistically significant improvements in neuropathy scores, quality of life, and TTR protein reduction in patients treated with Amvuttra compared to placebo [1].
What are the potential risks or side effects of Amvuttra?
Common side effects associated with Amvuttra include pain in the arms or legs, joint pain, and injection site reactions [1]. More serious potential risks include allergic reactions and changes in vitamin A levels, as Amvuttra can lower vitamin A levels in the blood [1]. Patients are advised to take vitamin A supplements as recommended by their healthcare provider [1].
How is Amvuttra administered and dosed?
Amvuttra is typically administered as a 29 mg subcutaneous injection every three months, after an initial loading dose [1]. The medication is self-administered by patients after proper training [1].
Are there patient support programs available for Amvuttra?
Manufacturers of Amvuttra often provide patient support programs to assist with access, insurance navigation, and adherence to treatment [1].
Who manufactures Amvuttra?
Amvuttra is manufactured by Alnylam Pharmaceuticals [1].
What is the current regulatory status of Amvuttra?
Amvuttra has received regulatory approval in several major markets, including the United States and Europe, for the treatment of hATTR amyloidosis [1].
Sources:
1. https://www.amvuttra.com/
2. https://www.alnylam.com/our-science/rna-interference-therapy
3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216634s000lbl.pdf
4. https://www.onpattro.com/
5. https://drugpatentwatch.com/